We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+4.86%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.07B
AUM Growth
+$160M
Cap. Flow
-$9.82B
Cap. Flow %
-121.72%
Top 10 Hldgs %
33.87%
Holding
157
New
25
Increased
29
Reduced
33
Closed
16

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$192M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$173M
3
MRK icon
Merck
MRK
+$94.1M
4
THC icon
Tenet Healthcare
THC
+$83.4M
5
DVA icon
DaVita
DVA
+$79.5M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$9.91B
2
LLY icon
Eli Lilly
LLY
+$193M
3
AMGN icon
Amgen
AMGN
+$156M
4
CI icon
Cigna
CI
+$151M
5
ELV icon
Elevance Health
ELV
+$148M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
2 Miscellaneous 1.49%
3 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTRS icon
101
CALL
Viatris
VTRS
$18.8B
$10.3M 0.13%
+250,000
New +$10.7M
NVO
102
CALL
Novo Nordisk
NVO
$188B
$9.85M 0.12%
+400,000
New +$10.5M
ADAP
103
DELISTED
Adaptimmune Therapeutics
ADAP
$9.73M 0.12%
866,593
-1,048,067
-55% -$9.17M
DBVT
104
DBV Technologies
DBVT
$750M
$9.47M 0.12%
41,070
-16,780
-29% -$3.97M
LAB icon
105
Standard BioTools
LAB
$273M
$9.25M 0.11%
1,583,700
– –
ALKS icon
106
Alkermes
ALKS
$7.55B
$8.4M 0.1%
145,000
– –
GWPH
107
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.34M 0.1%
74,000
+29,600
+67% +$3.72M
ATNX
108
DELISTED
Athenex, Inc. Common Stock
ATNX
$7.31M 0.09%
+21,500
New +$6.82M
NVTA
109
DELISTED
Invitae Corporation
NVTA
$7.12M 0.09%
1,518,197
– –
KIDS icon
110
OrthoPediatrics
KIDS
$603M
$6.4M 0.08%
425,200
– –
NBIX icon
111
Neurocrine Biosciences
NBIX
$15.5B
$6.22M 0.08%
+75,000
New +$6.33M
SNDX icon
112
Syndax Pharmaceuticals
SNDX
$1.59B
$6.22M 0.08%
437,000
– –
FOMX
113
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.64M 0.07%
+1,100,000
New +$6.62M
ALXN
114
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$5.57M 0.07%
+50,000
New +$5.98M
CRSP icon
115
CRISPR Therapeutics
CRSP
$5.03B
$4.77M 0.06%
+104,401
New +$4.31M
SRRA
116
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.56M 0.06%
55,093
-25,000
-31% -$2.83M
PRQR icon
117
ProQR Therapeutics
PRQR
$253M
$4.01M 0.05%
1,302,955
– –
TSRO
118
DELISTED
TESARO, Inc.
TSRO
$3.84M 0.05%
67,281
– –
SRPT icon
119
CALL
Sarepta Therapeutics
SRPT
$2.18B
$3.71M 0.05%
50,000
– –
CLVS
120
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.43M 0.04%
+65,000
New +$3.79M
TEVA icon
121
PUT
Teva Pharmaceuticals
TEVA
$44.9B
$3.42M 0.04%
+200,000
New +$3.9M
EXEL icon
122
CALL
Exelixis
EXEL
$13.7B
$3.32M 0.04%
+150,000
New +$4.15M
AUPH icon
123
Aurinia Pharmaceuticals
AUPH
$2.14B
$3.25M 0.04%
626,275
-1,171,125
-65% -$6.27M
XENE icon
124
Xenon Pharmaceuticals
XENE
$5.51B
$3.11M 0.04%
634,812
– –
RDHL
125
Redhill Biopharma
RDHL
$3.52M
$2.91M 0.04%
565
– –
3 4
5
6 7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2018 Portfolio in Review

As of Q1 2018, OrbiMed held 157 positions worth $8.07B, up 2% from $7.91B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $9.82B in Q1 2018, closing 16 positions and reducing 33 holdings. Its most notable exit was Eli Lilly, an estimated $193M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in ARMO BioSciences, Inc. Common Stock worth $154M.

  • OrbiMed's largest Q1 2018 buy was ARMO BioSciences, Inc. Common Stock: 4,118,903 shares worth $154M.
  • OrbiMed added most to Bristol-Myers Squibb in Q1 2018, an estimated $192M increase.
  • OrbiMed's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $9.91B.
  • OrbiMed fully exited Eli Lilly in Q1 2018, selling an estimated $193M.
  • OrbiMed's ten largest holdings make up 34% of its $8.07B portfolio in Q1 2018.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2018.
  • OrbiMed's portfolio value rose 2% quarter-over-quarter to $8.07B.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.